Neumora Therapeutics Inc 's (NMRA) Outlook - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 
Neumora Therapeutics Inc   (NASDAQ: NMRA)
 



  Neumora Therapeutics Inc Outlook

On May 7 2024 the Neumora Therapeutics Inc provided following guidance

Neumora Therapeutics Inc. has released their financial results for the first quarter of 2024 and also provided an update on their business operations. The company is currently on schedule to release the topline data from their Phase 3 study, KOASTAL-1, which is focused on evaluating the use of navacaprant in the treatment of Major Depressive Disorder (MDD). The company has adjusted their guidance and expects to report this data in the fourth quarter of 2024. This study is a significant milestone for Neumora Therapeutics as they continue to make progress in their efforts to develop new treatments for mental health conditions.





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.